Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease

Chengjie Xiong, Hua Weng, David A. Bennett, Patricia A. Boyle, Raj C. Shah, Scot Fague, Charles B. Hall, Richard B. Lipton, John C. Morris

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aims: Cognitive batteries routinely used by the Alzheimer's disease (AD) research community may contain items that are uninformative for tracking disease progression to power clinical trials on early stage AD. We aim to identify the subsets of the most informative items from an existing cognitive battery to better power clinical trials on early AD. Methods: Longitudinal change in item scores from the battery was associated with the onset of mild cognitive impairment (MCI) in 1,513 elderly individuals. Items whose longitudinal changes were correlated with the onset of MCI were selected as informative for tracking the early cognitive progression. Results: 226 items in the battery were annually assessed over a follow-up of up to 13 years. Changes of item scores over time from 187 items were significantly correlated with the onset of MCI. For clinical trials on preclinical AD and on MCI, informative items permit smaller or similar sample sizes as compared to the entire battery, whereas uninformative items require much larger sample sizes. Conclusions: Longitudinal changes in item scores from about 17% of items in the cognitive battery are uninformative for tracking early disease progression. Clinical trials on early AD can be better powered using informative items rather than the entire battery.

Original languageEnglish (US)
Pages (from-to)131-139
Number of pages9
JournalNeuroepidemiology
Volume43
Issue number2
DOIs
StatePublished - Apr 18 2014

Fingerprint

Alzheimer Disease
Clinical Trials
Sample Size
Disease Progression
Power (Psychology)
Cognitive Dysfunction
Research

Keywords

  • Alzheimer's disease
  • Clinical trial design
  • Cognitive decline
  • Mild cognitive impairment
  • Power

ASJC Scopus subject areas

  • Epidemiology
  • Clinical Neurology

Cite this

Xiong, C., Weng, H., Bennett, D. A., Boyle, P. A., Shah, R. C., Fague, S., ... Morris, J. C. (2014). Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease. Neuroepidemiology, 43(2), 131-139. https://doi.org/10.1159/000365733

Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease. / Xiong, Chengjie; Weng, Hua; Bennett, David A.; Boyle, Patricia A.; Shah, Raj C.; Fague, Scot; Hall, Charles B.; Lipton, Richard B.; Morris, John C.

In: Neuroepidemiology, Vol. 43, No. 2, 18.04.2014, p. 131-139.

Research output: Contribution to journalArticle

Xiong, C, Weng, H, Bennett, DA, Boyle, PA, Shah, RC, Fague, S, Hall, CB, Lipton, RB & Morris, JC 2014, 'Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease', Neuroepidemiology, vol. 43, no. 2, pp. 131-139. https://doi.org/10.1159/000365733
Xiong, Chengjie ; Weng, Hua ; Bennett, David A. ; Boyle, Patricia A. ; Shah, Raj C. ; Fague, Scot ; Hall, Charles B. ; Lipton, Richard B. ; Morris, John C. / Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease. In: Neuroepidemiology. 2014 ; Vol. 43, No. 2. pp. 131-139.
@article{56aaf0d0b3e84fbeafdda787276e9dc0,
title = "Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease",
abstract = "Background/Aims: Cognitive batteries routinely used by the Alzheimer's disease (AD) research community may contain items that are uninformative for tracking disease progression to power clinical trials on early stage AD. We aim to identify the subsets of the most informative items from an existing cognitive battery to better power clinical trials on early AD. Methods: Longitudinal change in item scores from the battery was associated with the onset of mild cognitive impairment (MCI) in 1,513 elderly individuals. Items whose longitudinal changes were correlated with the onset of MCI were selected as informative for tracking the early cognitive progression. Results: 226 items in the battery were annually assessed over a follow-up of up to 13 years. Changes of item scores over time from 187 items were significantly correlated with the onset of MCI. For clinical trials on preclinical AD and on MCI, informative items permit smaller or similar sample sizes as compared to the entire battery, whereas uninformative items require much larger sample sizes. Conclusions: Longitudinal changes in item scores from about 17{\%} of items in the cognitive battery are uninformative for tracking early disease progression. Clinical trials on early AD can be better powered using informative items rather than the entire battery.",
keywords = "Alzheimer's disease, Clinical trial design, Cognitive decline, Mild cognitive impairment, Power",
author = "Chengjie Xiong and Hua Weng and Bennett, {David A.} and Boyle, {Patricia A.} and Shah, {Raj C.} and Scot Fague and Hall, {Charles B.} and Lipton, {Richard B.} and Morris, {John C.}",
year = "2014",
month = "4",
day = "18",
doi = "10.1159/000365733",
language = "English (US)",
volume = "43",
pages = "131--139",
journal = "Neuroepidemiology",
issn = "0251-5350",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease

AU - Xiong, Chengjie

AU - Weng, Hua

AU - Bennett, David A.

AU - Boyle, Patricia A.

AU - Shah, Raj C.

AU - Fague, Scot

AU - Hall, Charles B.

AU - Lipton, Richard B.

AU - Morris, John C.

PY - 2014/4/18

Y1 - 2014/4/18

N2 - Background/Aims: Cognitive batteries routinely used by the Alzheimer's disease (AD) research community may contain items that are uninformative for tracking disease progression to power clinical trials on early stage AD. We aim to identify the subsets of the most informative items from an existing cognitive battery to better power clinical trials on early AD. Methods: Longitudinal change in item scores from the battery was associated with the onset of mild cognitive impairment (MCI) in 1,513 elderly individuals. Items whose longitudinal changes were correlated with the onset of MCI were selected as informative for tracking the early cognitive progression. Results: 226 items in the battery were annually assessed over a follow-up of up to 13 years. Changes of item scores over time from 187 items were significantly correlated with the onset of MCI. For clinical trials on preclinical AD and on MCI, informative items permit smaller or similar sample sizes as compared to the entire battery, whereas uninformative items require much larger sample sizes. Conclusions: Longitudinal changes in item scores from about 17% of items in the cognitive battery are uninformative for tracking early disease progression. Clinical trials on early AD can be better powered using informative items rather than the entire battery.

AB - Background/Aims: Cognitive batteries routinely used by the Alzheimer's disease (AD) research community may contain items that are uninformative for tracking disease progression to power clinical trials on early stage AD. We aim to identify the subsets of the most informative items from an existing cognitive battery to better power clinical trials on early AD. Methods: Longitudinal change in item scores from the battery was associated with the onset of mild cognitive impairment (MCI) in 1,513 elderly individuals. Items whose longitudinal changes were correlated with the onset of MCI were selected as informative for tracking the early cognitive progression. Results: 226 items in the battery were annually assessed over a follow-up of up to 13 years. Changes of item scores over time from 187 items were significantly correlated with the onset of MCI. For clinical trials on preclinical AD and on MCI, informative items permit smaller or similar sample sizes as compared to the entire battery, whereas uninformative items require much larger sample sizes. Conclusions: Longitudinal changes in item scores from about 17% of items in the cognitive battery are uninformative for tracking early disease progression. Clinical trials on early AD can be better powered using informative items rather than the entire battery.

KW - Alzheimer's disease

KW - Clinical trial design

KW - Cognitive decline

KW - Mild cognitive impairment

KW - Power

UR - http://www.scopus.com/inward/record.url?scp=84910091347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910091347&partnerID=8YFLogxK

U2 - 10.1159/000365733

DO - 10.1159/000365733

M3 - Article

VL - 43

SP - 131

EP - 139

JO - Neuroepidemiology

JF - Neuroepidemiology

SN - 0251-5350

IS - 2

ER -